Long term efficacy of DOTS regimens for tuberculosis: Systematic review

BMJ

Volumn 336, Issue 7642, 2008, Pages 484-487

  Cox, Helen S ^a,b   Morrow, Martha ^a   Deutschmann, Peter W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; COCHRANE LIBRARY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBASE; FOLLOW UP; GENETIC HETEROGENEITY; HEALTH PROGRAM; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RECURRENT DISEASE; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 40449090019     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39463.640787.BE     Document Type: Article

References (22)

1. WHO. WHO report on the tuberculosis epidemic, 1995. Stop TB at the source. Geneva: WHO, 1995. Report No WHO/TB/95.183.
2. Chiang CY, Riley LW. Exogenous reinfection in tuberculosis. Lancet Infect Dis 2005;5:629-36.
3. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005;171:1430-5.
4. WHO. Treatment of tuberculosis: guidelines for national programmes. Geneva: WHO, 2003. Report No WHO/CDS/TB/2003.313.
5. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004;364:1244-51.
6. Algerian Working Group/British Medical Research Council. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian Working Group/British Medical Research Council cooperative study. Am Rev Respir Dis 1984;129:921-8.
7. Balasubramanian VN, Oommen K, Samuel R. DOT or not? Direct observation of anti-tuberculosis treatment and patient outcomes, Kerala State, India. Int J Tuberc Lung Dis 2000;4:409-13.
8. Iseman MD. Good news and not such good news. Int J Tuberc Lung Dis 1999;3:87.
9. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database Syst Rev 2001;(4):CD000970.
10. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004;170:1124-30.
11. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003;37:101-12.
12. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-34.
13. Johnson JL, Okwera A, Vjecha MJ, Byekwaso F, Nakibali J, Nyole S, et al. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 1997;1:446-53.
14. Aber VR, Nunn AJ. [Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy]. Bull Int Union Tuberc 1978;53:276-80.
15. Banda H, Kang'ombe C, Harries AD, Nyangulu DS, Whitty CJ, Wirima JJ, et al. Mortality rates and recurrent rates of tuberculosis in patients with smear-negative pulmonary tuberculosis and tuberculous pleural effusion who have completed treatment. Int J Tuberc Lung Dis 2000;4:968-74.
16. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004;170:1360-6.
17. Dutt AK, Moers D, Stead WW. Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients. Am J Med 1984;77:233-42.
18. WHO. Global tuberculosis control, surveillance, planning, financing. Geneva: WHO, 2007. Report No WHO/HTM/TB/2007.376.
19. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005;293:2767-75.
20. Dye C, Maher D, Weil D, Espinal M, Raviglione M. Targets for global tuberculosis control. Int J Tuberc Lung Dis 2006;10:460-2.
21. Raviglione M. XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis 2006;10:1185-7.
22. Hargreaves S. Existing tuberculosis drugs may hold the key to shorter treatment. Lancet Infect Dis 2007;7:309.